PRINCETON, New Jersey, April 30, 2026
Made Scientific, a U.S.-based cell therapy contract development and manufacturing organization (CDMO), announced the expansion of its Board of Directors as part of a strategic move to support scale-up operations and commercial readiness in advanced therapy manufacturing. The company appointed Ted Dolan and Soyoung Park, joining an experienced leadership group including Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, under the leadership of Chairman and CEO Syed T. Husain. This development reflects a deliberate effort to align governance with the company’s transition toward late-phase and commercial-stage cell therapy manufacturing, where operational precision, scalability, and regulatory compliance become critical success factors.
Leadership Expansion Strengthens Operational and Strategic Capabilities
The newly strengthened board brings decades of combined expertise across CDMO operations, pharmaceutical manufacturing, global commercialization, and healthcare strategy, positioning Made Scientific to execute complex manufacturing programs at scale. Ted Dolan, with over 40 years of experience in drug substance, drug product, and analytical services, adds deep operational knowledge in scaling manufacturing infrastructure and managing late-stage programs.
Meanwhile, Soyoung Park’s expertise in bio-healthcare strategy and global advisory enhances the company’s ability to align with international partners and long-term growth strategies. This expanded leadership structure directly addresses the increasing complexity of cell therapy manufacturing, where transitioning from clinical to commercial production requires robust governance, disciplined execution, and strategic foresight.
Scaling GMP Manufacturing for Commercial Demand
Advertisement
The board expansion coincides with Made Scientific’s ongoing efforts to expand its GMP manufacturing capacity at its Princeton campus, driven by rising demand from advanced therapy developers. As cell therapy programs move closer to commercialization, manufacturers must ensure consistent product quality, regulatory compliance, and scalable production capabilities, all while managing highly personalized and complex therapies.
The company’s backing from GC Corporation, a global pharmaceutical and biotechnology leader, provides long-term financial stability and strategic support, enabling sustained investment in infrastructure and innovation. This partnership reinforces a long-term growth strategy focused on quality, scalability, and operational excellence, rather than short-term gains.
Positioning for Leadership in Cell Therapy Manufacturing
Made Scientific’s strategic focus reflects broader industry trends, where cell and gene therapies are rapidly advancing toward commercialization, creating demand for specialized CDMOs capable of handling complex biologics and personalized treatments. By strengthening its leadership team and expanding operational capacity, the company is positioning itself as a reliable partner for biopharma companies navigating late-stage development and commercial launch.
The combination of technical expertise, scalable infrastructure, and strategic governance enables Made Scientific to support both autologous and allogeneic cell therapy programs, ensuring readiness for the next wave of precision medicine and advanced therapeutics.
This move highlights the growing importance of experienced leadership and manufacturing scalability in the evolving cell therapy ecosystem, where execution capabilities can directly impact clinical success and market entry timelines. With a strengthened board and continued investment in infrastructure, Made Scientific is advancing toward becoming a key player in global cell therapy manufacturing and commercialization support.
Source: Made Scientific press release
